A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party

N. M. Bleehen; L. S. Freedman; S. P. Stenning

doi:10.1016/0360-3016(89)90920-6

A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party

N. M. Bleehen, L. S. Freedman, S. P. Stenning

U.K. to: Medical Research

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

In a randomized, double-blind study, 44 patients with recurrent high grade malignant glioma were allocated to chemotherapy of CCNU, with or without benznidazole (BENZO). Of 42 eligible patients, 23 received CCNU alone, and 19 CCNU received BENZO. Only 8 patients received the full 6 courses of treatment. The mean number of courses given was 2.8 for placebo and 3.4 for benznidazole patients. Progressive disease caused termination of treatment early for the majority of patients. There was no evidence of increased toxicity-leucopenia, anemia or thrombocytopenia-in the BENZO group, and only one patient in each treatment group had chemotherapy terminated because of toxicity. The BENZO group did not demonstrate any survival advantage: median survival time was 25 weeks in the BENZO group and 30 weeks in the placebo group. The confidence interval for the treatment difference is wide but excludes a BENZO-related addition of more than 7 months to the median survival time.

Original language	English
Pages (from-to)	1077-1081
Number of pages	5
Journal	International Journal of Radiation Oncology Biology Physics
Volume	16
Issue number	4
DOIs	https://doi.org/10.1016/0360-3016(89)90920-6
State	Published - Apr 1989
Externally published	Yes

Bibliographical note

Funding Information:
Report to the Medical Research Council by the Brain Tumor Working Party*

Funding Information:
Reprint requests to: Medical Research Council. Acknowledgements-We thank the following clinicians and their colleagues for their participation in the study: Dr. J. D. Bradshaw (Sheffield), Dr. J. Bullimore (Bristol), Dr. H. F. Hope-Stone (London), Dr. V. Levin (Groote Schuur), Dr. D. S. Murrell (Brighton), Dr. L. F. N. Senanayake (Royal Free) and Dr. J. Stone (Leeds). We would also like to thank Dr. D. Hawkins, reference neuroradiologist for the trial, and Mrs. Bethan Smith, who co-ordinated the data collection. Accepted for publication 10 November 1988.

Funding

Report to the Medical Research Council by the Brain Tumor Working Party* Reprint requests to: Medical Research Council. Acknowledgements-We thank the following clinicians and their colleagues for their participation in the study: Dr. J. D. Bradshaw (Sheffield), Dr. J. Bullimore (Bristol), Dr. H. F. Hope-Stone (London), Dr. V. Levin (Groote Schuur), Dr. D. S. Murrell (Brighton), Dr. L. F. N. Senanayake (Royal Free) and Dr. J. Stone (Leeds). We would also like to thank Dr. D. Hawkins, reference neuroradiologist for the trial, and Mrs. Bethan Smith, who co-ordinated the data collection. Accepted for publication 10 November 1988.

Funders	Funder number
Medical Research Council
Medical Research Council

Keywords

4
Astrocytoma grade 3
Benznidazole
CCNU
Chemosensitization

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0360-3016(89)90920-6

Cite this

Bleehen, N. M., Freedman, L. S., & Stenning, S. P. (1989). A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. International Journal of Radiation Oncology Biology Physics, 16(4), 1077-1081. https://doi.org/10.1016/0360-3016(89)90920-6

@article{7f31bdbcb4734fc6b856551917069cc9,

title = "A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party",

abstract = "In a randomized, double-blind study, 44 patients with recurrent high grade malignant glioma were allocated to chemotherapy of CCNU, with or without benznidazole (BENZO). Of 42 eligible patients, 23 received CCNU alone, and 19 CCNU received BENZO. Only 8 patients received the full 6 courses of treatment. The mean number of courses given was 2.8 for placebo and 3.4 for benznidazole patients. Progressive disease caused termination of treatment early for the majority of patients. There was no evidence of increased toxicity-leucopenia, anemia or thrombocytopenia-in the BENZO group, and only one patient in each treatment group had chemotherapy terminated because of toxicity. The BENZO group did not demonstrate any survival advantage: median survival time was 25 weeks in the BENZO group and 30 weeks in the placebo group. The confidence interval for the treatment difference is wide but excludes a BENZO-related addition of more than 7 months to the median survival time.",

keywords = "4, Astrocytoma grade 3, Benznidazole, CCNU, Chemosensitization",

author = "Bleehen, {N. M.} and Freedman, {L. S.} and Stenning, {S. P.}",

note = "Funding Information: Report to the Medical Research Council by the Brain Tumor Working Party* Funding Information: Reprint requests to: Medical Research Council. Acknowledgements-We thank the following clinicians and their colleagues for their participation in the study: Dr. J. D. Bradshaw (Sheffield), Dr. J. Bullimore (Bristol), Dr. H. F. Hope-Stone (London), Dr. V. Levin (Groote Schuur), Dr. D. S. Murrell (Brighton), Dr. L. F. N. Senanayake (Royal Free) and Dr. J. Stone (Leeds). We would also like to thank Dr. D. Hawkins, reference neuroradiologist for the trial, and Mrs. Bethan Smith, who co-ordinated the data collection. Accepted for publication 10 November 1988.",

year = "1989",

month = apr,

doi = "10.1016/0360-3016(89)90920-6",

language = "אנגלית",

volume = "16",

pages = "1077--1081",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "4",

}

Bleehen, NM, Freedman, LS & Stenning, SP 1989, 'A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party', International Journal of Radiation Oncology Biology Physics, vol. 16, no. 4, pp. 1077-1081. https://doi.org/10.1016/0360-3016(89)90920-6

A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. / Bleehen, N. M.; Freedman, L. S.; Stenning, S. P.
In: International Journal of Radiation Oncology Biology Physics, Vol. 16, No. 4, 04.1989, p. 1077-1081.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party

AU - Bleehen, N. M.

AU - Freedman, L. S.

AU - Stenning, S. P.

N1 - Funding Information: Report to the Medical Research Council by the Brain Tumor Working Party* Funding Information: Reprint requests to: Medical Research Council. Acknowledgements-We thank the following clinicians and their colleagues for their participation in the study: Dr. J. D. Bradshaw (Sheffield), Dr. J. Bullimore (Bristol), Dr. H. F. Hope-Stone (London), Dr. V. Levin (Groote Schuur), Dr. D. S. Murrell (Brighton), Dr. L. F. N. Senanayake (Royal Free) and Dr. J. Stone (Leeds). We would also like to thank Dr. D. Hawkins, reference neuroradiologist for the trial, and Mrs. Bethan Smith, who co-ordinated the data collection. Accepted for publication 10 November 1988.

PY - 1989/4

Y1 - 1989/4

N2 - In a randomized, double-blind study, 44 patients with recurrent high grade malignant glioma were allocated to chemotherapy of CCNU, with or without benznidazole (BENZO). Of 42 eligible patients, 23 received CCNU alone, and 19 CCNU received BENZO. Only 8 patients received the full 6 courses of treatment. The mean number of courses given was 2.8 for placebo and 3.4 for benznidazole patients. Progressive disease caused termination of treatment early for the majority of patients. There was no evidence of increased toxicity-leucopenia, anemia or thrombocytopenia-in the BENZO group, and only one patient in each treatment group had chemotherapy terminated because of toxicity. The BENZO group did not demonstrate any survival advantage: median survival time was 25 weeks in the BENZO group and 30 weeks in the placebo group. The confidence interval for the treatment difference is wide but excludes a BENZO-related addition of more than 7 months to the median survival time.

AB - In a randomized, double-blind study, 44 patients with recurrent high grade malignant glioma were allocated to chemotherapy of CCNU, with or without benznidazole (BENZO). Of 42 eligible patients, 23 received CCNU alone, and 19 CCNU received BENZO. Only 8 patients received the full 6 courses of treatment. The mean number of courses given was 2.8 for placebo and 3.4 for benznidazole patients. Progressive disease caused termination of treatment early for the majority of patients. There was no evidence of increased toxicity-leucopenia, anemia or thrombocytopenia-in the BENZO group, and only one patient in each treatment group had chemotherapy terminated because of toxicity. The BENZO group did not demonstrate any survival advantage: median survival time was 25 weeks in the BENZO group and 30 weeks in the placebo group. The confidence interval for the treatment difference is wide but excludes a BENZO-related addition of more than 7 months to the median survival time.

KW - 4

KW - Astrocytoma grade 3

KW - Benznidazole

KW - CCNU

KW - Chemosensitization

UR - http://www.scopus.com/inward/record.url?scp=0024322624&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(89)90920-6

DO - 10.1016/0360-3016(89)90920-6

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 2539345

AN - SCOPUS:0024322624

SN - 0360-3016

VL - 16

SP - 1077

EP - 1081

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 4

ER -

A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this